Sotrovimab News and Research

RSS
Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Drug-resistant SARS-CoV-2 variants found in immunocompromised patients

Cardiovascular risks of COVID-19 antivirals

Cardiovascular risks of COVID-19 antivirals

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

Research highlights emergence of immune-evasive SARS-CoV-2 variants in immunocompromised patients

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

New study offers clues on how to future-proof covid-19 vaccines

New study offers clues on how to future-proof covid-19 vaccines

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

The virological characteristics of XBB.1.16

The virological characteristics of XBB.1.16

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

mAb therapy reduces risk of hospitalization and death against Alpha, Delta, and Omicron variants

Real-world data on the effectiveness of Sotrovimab as a prophylactic against COVID-19

Real-world data on the effectiveness of Sotrovimab as a prophylactic against COVID-19

Bispecific antibody shows improved efficacy against SARS-CoV-2  variants

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Research reports full efficacy of Sotrovimab against BQ.1.1 viral replication in a non-human primate challenge model

Omicron BQ and XBB subvariants most resistant viruses to monoclonal antibodies

Omicron BQ and XBB subvariants most resistant viruses to monoclonal antibodies

The relationship between natural plant extracts and SARS-CoV-2

The relationship between natural plant extracts and SARS-CoV-2

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

Profound immune escape by SARS-CoV-2 XBB.1 even after 4 vaccine doses

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Does nirmatrelvir and ritonavir reduce the risk of hospitalization or death among outpatients with early COVID-19?

Characterization of immune evasion and cell entry for new variants: BQ.1.1, XBB.1, and BR.2.1

Characterization of immune evasion and cell entry for new variants: BQ.1.1, XBB.1, and BR.2.1

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

Among US veterans with COVID-19, few used antivirals or monoclonal antibodies

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.